Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-17
2007-07-17
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026230, C536S026260, C536S026700, C536S027200
Reexamination Certificate
active
10971477
ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:wherein, T, Y, W, W1and W2are as defined herein.
REFERENCES:
patent: 4140851 (1979-02-01), Townsend et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4927830 (1990-05-01), Townsend et al.
patent: 4968686 (1990-11-01), Townsend et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763597 (1998-06-01), Ugarkar et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5811534 (1998-09-01), Cook et al.
patent: 5824796 (1998-10-01), Petrie et al.
patent: 5844106 (1998-12-01), Seela et al.
patent: 6004939 (1999-12-01), Chen et al.
patent: 6054442 (2000-04-01), Chen et al.
patent: 6150510 (2000-11-01), Seela et al.
patent: 6211158 (2001-04-01), Seela et al.
patent: 6479651 (2002-11-01), Seela et al.
patent: 6593306 (2003-07-01), Chen et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 2002/0035077 (2002-03-01), Tam et al.
patent: 2003/0096981 (2003-05-01), Seela et al.
patent: 2003/0153744 (2003-08-01), Mekouar et al.
patent: 2004/0014108 (2004-01-01), Eldrup et al.
patent: 2004/0014957 (2004-01-01), Eldrup et al.
patent: 2004/0067901 (2004-04-01), Bhat et al.
patent: 2004/0072788 (2004-04-01), Bhat et al.
patent: 61-229897 (1986-10-01), None
patent: WO/1991/10671 (1991-07-01), None
patent: WO/1994/18215 (1994-08-01), None
patent: WO/1994/24144 (1994-10-01), None
patent: WO/1995/07919 (1995-03-01), None
patent: WO/1997/49833 (1997-12-01), None
patent: WO/2001/90121 (2001-05-01), None
patent: WO/2001/72764 (2001-10-01), None
patent: WO/2002/18404 (2002-03-01), None
patent: WO/2002/057287 (2002-07-01), None
patent: WO/2002/057425 (2002-07-01), None
patent: WO/2003/051899 (2003-06-01), None
patent: WO/2003/055896 (2003-07-01), None
patent: WO/2003/061576 (2003-07-01), None
patent: WO/2003/068244 (2003-08-01), None
patent: WO/2004/007512 (2004-01-01), None
patent: WO/2004/011478 (2004-02-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/043977 (2004-05-01), None
Bergstrom, et al. “Antiviral Activity of C-5 Substituted Tubercidin Analouges”J. Med. Chem.27:285-292 (1984).
Hobbs, F.W. “alladium-Catalyzed Synthesis of Alkynylamino Nucleosides. A niversal Liner for Nucleic Acids”J. Org. Chem.54:3420-3422 (1989).
DeClercq, et al. “Nucleic Acid Related Compounds. 51. Synthesis and Biological Properties of Sugar-Modified Analogues of the Nucleoside Antibiotics Tubercidin, Toyocamycin, Sangivamycin, and Formycin”J. Med. Chem.30:481-486 (1987).
Bzowska et al.; “7-Deazapurine 2′-deoxyribofuranosides are noncleavable competitive inhibitors ofEscherichia colipurine nucleoside phosphorylase (PNP),”Acta Biochimica Polonica, 45(3): 755-768 (1998).
Seela et al., “Pyrrolo[2,3d]Pyrididine Nucleosides: 7-Deaza-2′-Deoxyadenosines,”Nucleosides, Nucleotides&Nucleic Acids, 19(1&2):237-251 (2000).
Migliaccio et al., “Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro”J.Biol.Chem.278(49):49164-49170 (2003).
Carroll, et al., “Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs”J.Biol.Chem278(14):11979-11981 (2003).
Seela, et al, “Oligonucleoties containing 7-deazaadenines: the influence of the 7-substituent chain length and charge on the duplex stability,”Helvetica Cimica Acta., 82(11):1878-1898 (1999).
Rosemeyer, et al., “Stereoelectronic effects of modified purine bases on the sugar conformation of nucleosides: pyrrolo[2,3-d] pyrimidines,”Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry, 11:2342-2346 (1997).
Rosemeyer, et al., “Steric and stereoelectronic effects of 7-deazapurine bases on the sugar conformation of 2′-deoxynucleosides”Nucleosides&Nucleotides16(7-9) 1447-1451 (1997).
Rosemeyer, et al., “Stereoelectronic effects of modified purines on the sugar conformation of nucleosides and fluorescence properties,”Nucleosides&Nucleotides, 16(5&6):821-828 (1997).
Seela, et al., “Palladium-catalyzed cross coupling of 7-iodo-2′-deoxytubercidin with terminal alkynes”Synthesis6:726-730 (1996).
Schneller, et al., “Biological Activity and a modified synthesis of 8-Amino-3-β-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, and isomer of formycin,”J. Med. Chem.27, 924-928 (1984).
Giziewicz, et al., “Antiviral and antimetabolic activities of formycin and its N-, N2-, 2′-O- and 3′-O-methylated derivatives,”Biochemical Pharmacology24, 1813-1817, (1975).
Bergstrom, et al., Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotic Analogues. Synthesis via Organopalladium Intermediates Derived from 5-Mercuritubercidin,J. Org Chem.46:1423-1431 (1981).
Sharma, et al., “Synthesis of 5′-Substituted Derivatives of the Pyrrolo [2,3-d]-Pyrimidine Nucleoside Sangivamycin and their Effect on Protein Kinase A and C Activity,”Nucleosides&Nucleotides12(3&4) 295-304 (1993).
Müller, et al., “7-Deaza-2-phenyladenines: Structure-Activity Relationship of Potent A1 Selective Adenosine Receptor Antogonists” J. Med. Chem. 33:2822-2828 (1990).
Limori, et al., “2′-C-, 3′-C- and 5′-C-Methylsangivamycins: Conformational Lock With The Methyl Group,” Tetrahedrom Letters 32(49) 7273-7276 (1991).
Kondo, et al., “Synthesis of 5-Methyltubercidin and its α-Anomer via Condensation of the Anion of 4-Methoxy-5-methyl-2-methylthiopyrrolo [2, 3-d] pyrimidine and 2, 3,5-Tri-O-benzyl-D-ribofuranosyl Bromide,”Agric.Biol.Chem.41(8):1501-1507 (1977).
Uematsu, et al., “5-Hydroxymethytubercidin, Synthesis, Biological Activity, and Role in Pyrrolopyrimidine Biosynthesis,” J. of Med.Chem, 16(12):1405-1407(1973).
Schramm, et al., “Pyrrolopyrimidine Nucleosides VIII. Synthesis of Sangivamycin Derivatives possessing exocyclic heterocycles at C 5”J. Carbohydrates, Nucleosides, Nucleotides1(1):39-54 (1974).
Murai et al. “A Synthesis and an X-Ray Analysis of 2′-C,3′-C- And 5′-C-Methylsangivamycins”Heterocycles33:391-404 (1992).
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo. Research, 166:219-232 (1987).
Dyatkina Natalia B.
Keicher Jesse D.
Roberts Christopher D.
Crane L. E.
Foley & Lardner LLP
Genelabs Technologies, Inc.
Yang Junrui
LandOfFree
Nucleoside compounds for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside compounds for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside compounds for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3770749